Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle.
Pöllänen. Eija E; Ronkainen. Paula H A PH; Horttanainen. Mia M; Takala. Timo T; Puolakka. Jukka J; Suominen. Harri H; Sipilä. Sarianna S; Kovanen. Vuokko V
Key Findings
- HRT increased IGF‑1 and its splice variant IGF‑1Ec (MGF) in skeletal muscle
- Higher IGF‑1Ec levels correlated with greater muscle size after one year
- mTOR and FOXO3 were also up‑regulated, while Akt1 was down‑regulated in HRT users
- C2C12 muscle cells did not replicate the gene changes seen in humans
Practical Outcomes
- For biohackers, combined estrogen‑progestin therapy may help preserve or grow muscle mass after menopause by boosting the body’s own MGF pathway. The protocol used 2 mg estradiol and 1 mg norethisterone acetate daily for a year, but benefits likely depend on the whole hormonal milieu, not just isolated compounds. Direct MGF peptide supplementation isn’t addressed, so use this insight mainly to consider hormone strategies rather than peptide dosing.
Summary
A year‑long hormone replacement therapy (2 mg estradiol + 1 mg norethisterone acetate) in post‑menopausal women raised the muscle’s own MGF (IGF‑1Ec) and other growth‑related genes, which was linked to bigger muscles. Lab cells didn’t show the same effect, suggesting the whole‑body environment matters.
Abstract
To investigate the effects of combined hormone replacement therapy (HRT) and its effective agents on the IGF-1 signaling pathway. To examine the effects of HRT on skeletal muscle in vivo, we utilized pre- and post-intervention samples from a randomized double blinded trial with 50-57-year-old women. The intervention included the year-long use of either HRT preparation (2 mg 17β-estradiol, E₂; 1mg norethisterone acetate, NETA, n=10) or placebo (CO, n=9). Microarray technology and quantitative PCR (qPCR) were used to study the expression of insulin-like growth factor I (IGF-1) and its splice variants as well as IGF-1 receptor, Akt1, mTOR, FOXO1, FOXO3, atrogin, estrogen receptors and androgen receptor in muscle samples. Serum concentrations of IGF-1, E(2) and testosterone were measured. C2C12 myotubes were fed with E₂ or NETA followed by analyzing the expression of essentially the same gene transcripts as in human samples by qPCR and phosphorylation of Akt and mTOR by Western blotting. The gene expression of IGF-1 and its splice variant, IGF-1Ec (also known as the mechano growth factor or MGF), mTOR, FOXO3, and AR was up-regulated among the HRT users compared to the CO (P<0.05), while Akt1 was down-regulated (P<0.05). The change in the level of IGF-1Ec transcript correlated positively with muscle size at post-intervention (r=0.5, P<0.05). In C2C12 myotubes, no statistically significant effects of either E₂ or NETA at the level of gene transcripts studied were identified. The amount of phosphorylated Akt appeared to respond to NETA, albeit the response was not statistically significant. Phosphorylation of mTOR did not respond to either of the treatments. Year-long postmenopausal HRT was found to affect the expression of the genes along the IGF-1 signaling cascade reflecting the higher muscle mass compared to the CO women. By using cell culture model we were, however, unable to confirm the possible differential role of E₂ and NETA. It appears that the synchronous presence of both effective agents of the HRT or the presence of yet unidentified microenvironmental factors providing proper paracrine signals naturally existing in the intact muscle tissue is critical for appropriate signaling via sex steroid-IGF-1 axis to occur.
Study Information
pubmed
2010
2010-08-17T00:00:00.000Z
10.1016/j.ghir.2010.07.003
55
56